Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities:~  * Follicular lymphoma grade 1 and 2~ * Immunocytoma and lymphoplasmocytic lymphoma~ * Marginal zone lymphoma, nodal and generalised~ * Mantle cell lymphoma~ * lymphocytic lymphoma (CLL without leucaemic characteristics)~ * non-specified/classified lymphomas of low malignancy~* No prior therapy with cytotoxics,interferon or monoclonal antibodies~* Need for therapy, except mantle cell lymphomas~* Stadium III or IV~* Written informed consent~* Performance status WHO 0-2~* Histology not older than 6 months~Exclusion Criteria:~* Patients not establishing all above mentioned prerequisites~* Option of a primary, potential curative radiation therapy~* Pretreatment except a unique local delimited radiation (radiation fiel not expanding two adjacent lymph node regions~* Comorbidities excluding a study conform therapy:~  * heart attack during the last 6 months~ * severe, medicinal not adjustable hypertonia~ * severe functional defects of the heart (NYHA III or IV)~ * lung (WHO grade III or IV), liver or kidney (creatinine \> 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bendamustine + Rituximab (Type: EXPERIMENTAL): Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
- CHOP + Rituximab (Type: ACTIVE_COMPARATOR): Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w

Based on this trial design, predict the completion outcome and termination type (if applicable).